Company Overview and News

 
Tokyo stocks rise for fifth session but topside capped by selling to lock in profits

2018-09-20 japantimes.co.jp
Stocks gained ground for the fifth straight session, albeit marginally, on the Tokyo Stock Exchange on Thursday, although their topside was capped by selling to lock in profits.
6506 YASKY 8035 TOELF 8630 YASKF TOELY

2
Tokyo stocks rise further on easing U.S.-China trade concerns

2018-09-19 japantimes.co.jp
Stocks continued to rise on the Tokyo Stock Exchange on Wednesday as investors were relieved that the economic impact of the latest development of U.S.-China trade friction is likely to be limited.
ADTTF TM SMFG TYT SFTBF TOYOF SMFNF TOELY SUOPY 8316 8306 7203 MUFG 9984 SUMCF 8750 TOELF 8035 MBFJF ATEYY MTU SFTBY

 
Asia Markets: Asian markets mostly shrug off latest U.S. tariffs targeting China

2018-09-18 marketwatch
Asian stock markets were mixed in early trading Tuesday, as investors generally shrugged off the latest round of U.S. tariffs on $200 billion of Chinese goods set to go into effect next week.
8035 TOELF TOELY

 
Nikkei rallies, finishes day on seven-month high of 23,094

2018-09-14 japantimes.co.jp
Stocks rose further on the Tokyo Stock Exchange on Friday thanks to the yen’s drop against the dollar, with the benchmark Nikkei average hitting a seven-month closing high above 23,000.
8035 TOELF TOELY

 
Nikkei posts best weekly gain in 2 months as trade anxiety eases

2018-09-14 reuters
TOKYO, Sept 14 (Reuters) - Japan’s Nikkei share average rallied to its highest in more than seven-months on Friday as sentiment improved on signs China and the United States make progress towards resolving their trade disputes.
6506 ADTTF TTDKF YASKY 8035 TOELF ATEYY YASKF TOELY

 
Nikkei jumps to over 7-month high

2018-09-14 thehindubusinessline
The Nikkei gained 1.0 per cent to 23,042.83 at the midday break, after rising as high as 23,053.10 to hit the highest point since early February. - Reuters
6506 ADTTF TTDKF YASKY 8035 TOELF ATEYY YASKF TOELY

 
Nikkei rises to over 7-month highs as trade anxiety ebbs slightly

2018-09-14 reuters
TOKYO, Sept 14 (Reuters) - Japan’s Nikkei share average rallied to over a seven-month high on Friday morning as sentiment improved on signs China and the United States could set aside their differences and resolve a heated trade dispute.
6506 ADTTF TTDKF YASKY 8035 TOELF ATEYY YASKF TOELY

 
Nikkei rallies on fading U.S-China trade jitters

2018-09-13 japantimes.co.jp
Stocks staged a strong rally Thursday as worries about the fierce trade friction between the United States and China began to recede.
8035 TOELF TOELY

3
Nikkei soars as Sino-U.S. trade talk hopes lift stocks sensitive to China demand

2018-09-13 reuters
TOKYO, Sept 13 (Reuters) - Japan’s Nikkei rallied to near two-week highs on Thursday as news of a proposed fresh round of trade talks between China and the United States lifted risk appetite, triggering buying in stocks which are exposed to Chinese demand.
KMTUF ADTTF TTDKF MU MRAAF MRAAY 8035 TOELF ATEYY TOELY

3
Nikkei rises to near 2-week highs on Sino-U.S. trade talk hopes

2018-09-13 theedgemarkets
TOKYO (Sept 13): Japan's Nikkei rallied to near two-week highs on Thursday morning after news of a fresh round of trade talks between China and the United States lifted risk appetite, triggering buying in stocks which are sensitive to demand in China.
KMTUF ADTTF TTDKF MU MRAAF MRAAY 8035 TOELF ATEYY TOELY

3
Nikkei rises to near 2-week highs on Sino-U.S. trade talk hopes

2018-09-13 reuters
TOKYO, Sept 13 (Reuters) - Japan’s Nikkei rallied to near two-week highs on Thursday morning after news of a fresh round of trade talks between China and the United States lifted risk appetite, triggering buying in stocks which are sensitive to demand in China.
KMTUF ADTTF TTDKF MU MRAAF MRAAY 8035 TOELF ATEYY TOELY

18
Why Goldman Sachs and Others See More Weakness Across Semiconductor Sector

2018-09-12 247wallst
If you have been tracking the activity in technology stocks in recent weeks, it has been hard to not notice the meltdown that has taken place in the various areas tied to semiconductors. What was running as an industry in supply shortages has started to become an industry facing oversupply. It’s a cycle that has happened dozens of times over the decades, but 24/7 Wall St. recently warned its readers that the analyst downgrades were probably far from being over, after seeing that the consensus analyst price targets were all still way too optimistic.
LRCX ENTG MU AAPL NXPI WDC STX 8035 TOELF MXIM POWI TOELY

 
Japan stocks rise on weaker yen, Nasdaq gain; US deal lifts Renesas

2018-09-11 reuters
TOKYO, Sept 11 (Reuters) - Japanese stocks had their best day in four weeks on Tuesday, with exporters lifted by the yen’s weakening against the dollar and technology shares boosted by gains for Wall Street counterparts.
ADTTF BRDCF TM RNECF TYT TOYOF TOELY KYO SUOPY 6723 7203 IDTI RNECY SUMCF 8035 TOELF ATEYY

 
Nikkei rises as yen, Nasdaq boost exporters, tech shares

2018-09-11 thehindubusinessline
Japanese stocks rose on Tuesday, with exporters lifted by the yen's weakening against the dollar and technology shares taking heart from gains in their American peers. The Nikkei share average was 0.91 per cent higher at 22,575.43.
ADTTF BRDCF TM RNECF TYT TOYOF TOELY KYO SUOPY 6723 7203 IDTI RNECY SUMCF 8035 TOELF ATEYY

 
Japan stocks gain as yen, Nasdaq boost exporters and tech shares

2018-09-11 reuters
TOKYO, Sept 11 (Reuters) - Japanese stocks rose on Tuesday, with exporters lifted by the yen’s weakening against the dollar and technology shares taking heart from gains in their American peers.
ADTTF BRDCF TM RNECF TYT TOYOF TOELY KYO SUOPY 6723 7203 IDTI RNECY SUMCF 8035 TOELF ATEYY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 006895675